Back to Top

National Blood Clot Alliance

1-877-466-2568

www.stoptheclot.org

 

The National Blood Clot Alliance (NBCA) is a 501(c)(3), non-profit, voluntary health organization dedicated to advancing the prevention, early diagnosis and successful treatment of life-threatening blood clots such as deep vein thrombosis, pulmonary embolism, and clot-provoked stroke. NBCA works on behalf of people who may be susceptible to blood clots, including, but not limited to, people with clotting disorders, atrial fibrillation, cancer, traumatic injury, and risks related to surgery, lengthy immobility, child birth and birth control. NBCA accomplishes its mission through programs that build public awareness, educate patients and healthcare professionals, and promote supportive public and private sector policy.

National Blood Clot Alliance News


  • June e-Newsletter | Summer Months, Summer Fun

    Jun 21, 2018

    Each year, more than 300 million people travel on long-distance flights (more than four hours long), with the total number of long-distance trips (about 657 million) happening from Memorial Day to Labor Day. The summer months are, in fact, the[…]

    Read more...
  • May e-Newsletter | Celebrate & Share During National Women’s Health Week

    May 17, 2018

    Join the National Blood Clot Alliance (NBCA) during National Women’s Health Week (NWHW), May 13-19, 2018, as we work with the Alexandra L. Rowan Memorial Foundation to provide women with life-saving information about birth control and blood clots, and to help them[…]

    Read more...
  • Celebrate & Share During National Women’s Health Week

    May 7, 2018

    Birth Control and Blood Clots: Know Your Risk There are more than 60 million women of child-bearing age in the United States, and the majority of them report using some form of birth control. In fact, the birth control pill is[…]

    Read more...
  • FDA Approves Andexxa®

    May 4, 2018

    NEW DRUG APPROVAL: The U.S. Food & Drug Administration (FDA) has granted Portola Pharmaceuticals approval to market Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote indicated to reverse the anticoagulation effects of factor Xa inhibitors, such as[…]

    Read more...